Evidence map›Paper›PMID 41784331›Full record

ArticleInfluenza and other respiratory viruses2026

Introducing the Concept of Small Vulnerable Newborns (SVN) as an Additional Endpoint to Evaluate Birth Outcomes in the Context of RSV Immunization Studies-A Commentary.

Jacob Gerstenberg, Carlotta Helbig, Benjamin T Schleenvoigt

Abstract read
In one paragraph

Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jacob GerstenbergInstitute of Infectious Diseases and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.ORCID https://orcid.org/0009-0008-1604-9710
Carlotta HelbigInstitute of Infectious Diseases and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.ORCID https://orcid.org/0009-0004-9274-5911
Benjamin T SchleenvoigtInstitute of Infectious Diseases and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.ORCID https://orcid.org/0000-0003-4678-2469

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infection with respiratory syncytial virus (RSV) represents a substantial burden of disease, especially in children. While one vaccine (RSVpreF) has been recommended for administration in pregnant women, another one (RSVPreF3-Mat) has been discontinued in a Phase 3 study due to an increased incidence of preterm births in the study group. When comparing the studies related to these two vaccine candidates, the differences in preterm birth rates appear inconsistent. For a more differentiated evaluation of birth outcomes associated with maternal RSV vaccination, we recommend introducing the previously described concept of "small and vulnerable newborns."

Indexed as

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesFemaleHumansInfant, NewbornPregnancyPregnancy Complications, InfectiousPremature BirthVaccinationRespiratory Syncytial Virus Vaccines

Identifiers

PMID41784331
PMCPMC12961912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.